Panthera Biopartners
Claire Scott has a wealth of experience in the medical field. Claire began their career in 2006 as a Post-doctoral Research Assistant at the University of Dundee, where they investigated the role of the Sprouty2 protein in pulmonary development and disease, and used the model organism Dictyostelim discoideum to elucidate the role played by cGMP in the life cycle and dormancy of the amoeba. In 2008, they moved to Aptuit as a Scientist. Claire then returned to the University of Dundee in 2009 as a Post-doctoral Research Assistant, where they sequenced and performed bioinformatic analysis of the Polysphondylium pallidum genome. In 2012, they joined Kyowa Kirin International plc. as a Medical Affairs Specialist. In 2016, they moved to NHS National Services Scotland as a Clinical Research Coordinator. Finally, in 2019, they joined Tissue Solutions Limited as a Clinical Alliances Manager, and in 2021 they began working as a Site Manager at Panthera Biopartners.
Claire Scott began their educational journey in 1997 when they attended Adam Smith College, where they earned an HND in Biology/Biological Sciences, General. Claire then proceeded to the University of Dundee, where they earned a BSc Hons in Molecular Genetics in 2002. Claire continued their studies at the University of Dundee, obtaining a PhD in Molecular pharmacology in 2006.
This person is not in any offices
Panthera Biopartners
1 followers
Panthera Biopartners, established in 2019, is a leading UK-based Site Management Organisation (SMO) specialising in patient recruitment and the execution of clinical trials across various therapeutic areas. Founded by Dr Ian Smith, the originator of Synexus, and Professor John Lyon, a former global executive at Covance, Panthera has rapidly expanded its network to include dedicated clinical trial sites in major UK cities such as Glasgow, London, Manchester, Preston, Sheffield and York The organisation's mission is to enhance healthcare accessibility by conducting clinical research that integrates diverse insights and expertise. Panthera is committed to maintaining rigorous ethical standards and contributing to medical advancements that positively impact health and well-being. Panthera's management team comprises experienced professionals with extensive knowledge in conducting clinical trials across multiple therapy areas and countries. Key figures include Dr Ian Smith (Co-Founder, Director, and Chief Medical Officer), Stuart Young (Chief Executive Officer), and Chris Dodd (Chief Commercial Officer). In October 2024, Panthera became the first UK clinical trial site organisation to join Parexel’s Site Alliance Vaccine Network, a global consortium of high-performing clinical trial sites. This collaboration underscores Panthera's exceptional performance in patient recruitment and its strong partnership with Parexel. Panthera's dedication to innovation and excellence was recognised in October 2023 when it was named Pharma Research Centre of the Year at the Pharma Industry Awards UK. The award highlighted Panthera's innovative SMO model, which emphasises rapid start-up times, access to a vast pool of prequalified patients, and the digitisation of patient engagement processes.